Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2013 August;65(4) > Minerva Pediatrica 2013 August;65(4):353-60

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA PEDIATRICA

A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,764


eTOC

 

ORIGINAL ARTICLES  


Minerva Pediatrica 2013 August;65(4):353-60

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Lactobacillus paracasei subsp. paracasei F19 in Bell’s Stage 2 of necrotizing enterocolitis

Zampieri N. 1, Pietrobelli A. 2, Biban P. 3, Soffiati M. 3, Dall’Agnola A. 4, Camoglio F. S. 4

1 Department of Anesthetic and Surgical Sciences Pediatric Surgical Unit University of Verona, Verona, Italy; 2 Department of Pediatrics Pediatric and Neonatal Intensive Care Unit University of Verona, Policlinico “G.B. Rossi”, Verona, Italy; 3 Department of Pediatrics Pediatric and Neonatal Intensive Care Unit Civile Maggiore Hospital, Verona, Italy; 4 Department of Pediatrics, Neonatal Unit, Orlandi General Hospital Bussolengo, Verona, Italy


PDF  


Aim: The aim of this trial is to evaluate the role Lactobacillus paracasei in Bell’s stage 2 in order to prevent the clinical progression to stage 3.
Methods: A prospective study was approved and started in December 2008. Patients were infants with birth weight 600 to 1500 g. One group received probiotic supplementation (L. paracasei susp.paracasei F-19) and the control group received only standard medical treatment. The primary outcome was the progression to stage 3 as defined by Bell’s modified criteria. Inclusion and exclusion criteria were created and discussed with parents before treatment.
Results: Thirty-two patients (stage 2 NEC) were considered eligible for the study. Group A: 18 patients and Group B: 14 patients. Three patients in group A and six patients in group B had a clinical history of Bell’s stage 3 NEC (P<0.05); oral supplementation of L. paracasei reduced the clinical progression of NEC. It was considered that an improvement in intestinal motility might have contributed to this result.
Conclusion: The use of Lactobacillus paracasei subsp. paracasei F-19 is safe; the low progression rate to stage 3 NEC suggests that the use of this probiotic in stage 2 NEC could be a valuable therapeutic option.

top of page

Publication History

Cite this article as

Corresponding author e-mail

dr.zampieri@libero.it